Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

2002 • 4,334 citations

Epigenetics in human disease and prospects for epigenetic therapy

2004 • 3,142 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

Histone deacetylases and cancer: causes and therapies

2001 • 1,833 citations

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

2001 • 1,816 citations

Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen

2001 • 1,684 citations

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

2002 • 1,497 citations

Histone deacetylase inhibitor selectively induces p21 ^WAF1 expression and gene-associated histone acetylation

2000 • 1,091 citations

The promise of retinoids to fight against cancer

2001 • 763 citations

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1999 • 686 citations

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

2003 • 517 citations

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

2003 • 464 citations

Regulation of the activity of Sp1-related transcription factors

2002 • 445 citations

Targeting death receptors in cancer with Apo2L/TRAIL

2004 • 367 citations

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL

2001 • 344 citations

Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives

1999 • 286 citations

Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway

2003 • 255 citations

Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.

2001 • 241 citations

Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

2003 • 232 citations

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

2001 • 204 citations

Sp1 and Sp3 Recruit Histone Deacetylase to Repress Transcription of Human Telomerase Reverse Transcriptase (hTERT) Promoter in Normal Human Somatic Cells

2002 • 178 citations

Transcription factor Sp3 is regulated by acetylation

2001 • 150 citations

Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL

2004 • 140 citations

Acetylated Sp3 Is a Transcriptional Activator

2003 • 126 citations

Histone deacetylase inhibitors induce caspase‐dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)

2001 • 93 citations

Targeted Histone Deacetylase Inhibition for Cancer Therapy

2004 • 92 citations

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

2002 • 91 citations

Effects of Novel RAR- and RXR-Selective Retinoids on Myeloid Leukemic Proliferation and Differentiation In Vitro

1999 • 51 citations

Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site

2003 • 50 citations